Executive summary of the KDIGO 2022 Clinical Practice Guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease

• Main Authors: Martin, Paul, Awan, Ahmed A., Berenguer, Marina C., Bruchfeld, Annette, Fabrizi, Fabrizio, Goldberg, David S., Jia, Jidong, Kamar, Nassim, Mohamed, Rosmawati, Pessoa, Mario Guimaraes, Pol, Stanislas, Sise, Meghan E., Balk, Ethan M., Gordon, Craig E., Adam, Gaelen, Cheung, Michael, Earley, Amy, Jadoul, Michel
• Format: Article
• Published: Elsevier Science Inc 2022
• Subjects: RC Internal medicine
• Online Access: http://eprints.um.edu.my/46166/; https://doi.org/10.1016/j.kint.2022.07.012

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.